Preventive measures against skin melanoma like chemotherapy are useful but suffer from chronic side effects and drug resistance. Ethanolic extract of Phytolacca decandra (PD), used in homeopathy for the treatment of various ailments like chronic rheumatism, regular conjunctivitis, psoriasis, and in some skin diseases was tested for its possible anticancer potential.
Introduction
A dynamic increase of skin melanoma mortality rate has been observed in the world in recent years. Though this type of skin cancer comprises just 5 % of all malignant skin cancers, it is responsible for a 75%-80% of deaths caused by these tumors [1] . The high rate of malignancy
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Journal of Integrative Medicine www.jcimjournal.com/jim of this neoplasm is associated with rapid proliferation, numerous early metastases and high resistance to conventional treatments involving surgery, chemotherapy and radiation. Although preventive measures like chemotherapy are very useful, these often result in manifestation of chronic side effects [2, 3] . Therefore, there is a growing demand for the development of alternative antimelanoma therapies with less side effects. Natural products of various sources, particularly from plants, have been regarded as a precious alternative to modern medicine and investigations on active components with anticancer potential and less side effects have opened up newer avenues [4] . In cancer treatment, one of the approaches to restrain tumor growth is by activating the apoptotic machinery in the tumor cells [5] . Apoptosis, a highly structured and orchestrated process, performs a significant role in regulating cell number for the growth and homeostasis of tissues by eliminating aged, damaged and unwanted cells [6, 7] . Phytolacca decandra (PD), commonly known as poke root, is an ornamental plant of the Phytolaccaceae family. Phytochemical characterisation revealed that terpenoids, saponins, alkaloid, resins, phytolacic acid and tannin are the major bioactive ingredients of Phytolacca species [8] [9] [10] [11] . From a long time Phytolacca has been used to combat different ailments in complementary and alternative medicine (CAM). In homeopathy, mother tincture of Phytolacca is used against chronic rheumatism, regular conjunctivitis, psoriasis and some skin diseases [12] . Although to the best of our knowledge, anticancer potential of the ethanolic crude extract of PD is yet to be systematically studied for scientific validation, stray reports exist in literature enlisting some of the ingredients like saponins and alkaloids extracted and separated from other plant sources to have anticancer potentials [13, 14] . Since the crude extract of PD is used in homeopathy, and since no earlier study appears to have been conducted on the anticancer effect on the basis of a reliable investigation, we undertook this research. Therefore, in the present set of experiment our main aim was to explore the anticancer activity, if any, of PD against A375 cells in vitro and if positive findings were obtained, to investigate the mode of cell death involved.
Materials and methods

Chemicals and reagents
Plastic wares were obtained from BD Bioscience (USA). Cell culture media Dulbecco's modified Eagle medium (DMEM) and Roswell Park Memorial Institute (RPMI), fetal bovine serum (FBS) and trypsin-ethylene diamine tetraacetic acid (trypsin-EDTA) were purchased from Invitrogen-Gibco BRL (USA). Primary and secondary antibodies were purchased from Santa Cruz Biotecnology (USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sisco Research Laboratory, India. TRIzol and antibiotics penicillin-streptomycin-neomycin (PSN) were obtained from HiMedia (India). Dichloro-dihydrofluorescein diacetate (H 2 DCFDA) and 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Sigma (USA). RNase and p-nitrophenyl phosphate (PNPP) were purchased from Merck (Germany). All the primers used were obtained from Bioserve (India). Ethanolic extract of PD in the form of homeopathic mother tincture was supplied by Boiron Laboratory, Lyon, France. They prepared the drug adopting the guidelines of European Pharmacopoeia and supplied the drug in 65% ethanolic extract. Before the experimental treatment, the drug was diluted in the DMEM media.
Cell culture
A375 and HeLa (National Centre for Cell Science, NCCS, India) cells were cultured in DMEM, whereas PC3 cells (NCCS, India) were cultured in RPMI, supplemented with 10% heat-inactivated FBS and 1% PSN and maintained at 37 ºC with 5% CO 2 in a humidified incubator (Thermo Scientific, USA). Cells were harvested with 1 × trypsin-EDTA in phosphate buffered saline (PBS) and plated at required cell numbers and allowed to adhere before treatment.
Cell viability assay
Cells were dispensed in 96-well plates at a density of 1×10 2 cells per well and treated with various concentrations of PD (0 to 780 µg/mL) for 24 and 48 h respectively and peripheral blood mononuclear cells (PBMCs) were isolated from the human blood sample by conventional ficoll gradient method and treated with PD at different concentrations (0 to 780 µg/mL), and incubated for 24 and 48 h. The percentage of cell death was determined by MTT assay [15] .
Selection of drug doses
On the basis of the result of MTT assay, we selected three different drug doses, namely, D1 (100 µg/mL), D2 (150 µg/mL) and D3 (200 µg/mL), for experiments and treated for 48 h on A375 cells. To calculate the concentration of the drug, the dry weight of PD was measured and expressed as drug doses in concentration unit (µg/mL). The positive (vehicle) control set received only ethanol (placebo) and the negative control neither received any drug nor ethanol. As the positive control had no significant change with respect to the negative control, we did not include negative control group in our experiments.
Morphological changes
Cells were treated with PD at specified concentrations. After 48 h, the cells were observed under an inverted light microscope (Leica, Germany) equipped with a digital Journal of Integrative Medicine camera and photographs were taken.
Nucleosomal fragmentation analysis
Treated cells were stained with DAPI (10 µg/mL) and analyzed under a fluorescence microscope (Axioscope 2 Plus, Carl Zeiss, Germany) and representative photographs were taken.
Lactate dehydrogenase-based cytotoxicity assay
Lactate dehydrogenase (LDH) activity was assessed using a standardized kinetic determination kit (Enzopak, Recon, India). LDH activity was measured according to the method of Biswas et al [16] . LDH activity was measured in both floating dead cells and adherent viable cells for control and drug-treated cells. The floating cells were collected from culture medium by centrifugation (500 × g) at 4 ºC for 2 min, and the LDH content from the pellets was used as an index of apoptotic cell death (LDHp). The LDH released in the culture supernatant (designated as extracellular LDH (LDHe)) was used as an index of necrotic death, and the LDH present in the adherent viable cells was designated as intracellular LDH (LDHi). The percentages of apoptotic and necrotic cell deaths were calculated as follows:
Apoptosis percentage = (LDHp × 100%)/(LDHp+LDHi+ LDHe)
Necrosis percentage = (LDHe × 100%)/(LDHp+LDHi+ LDHe)
Analysis of intracellular reactive oxygen species generation
Treated fixed cells were incubated with 10 µmol/L H 2 DCFDA and photographed under a fluorescence microscope (Leica DMLS, Germany) for qualitative analyses. For the quantitative estimation of reactive oxygen species (ROS) generation, the treated cells were fixed in 70% chilled methanol and incubated with 10 µmol/L H 2 DCFDA for 30 min at room temperature in dark. Fluorescence intensity was measured with an excitation wavelength of 480 nm and an emission wavelength of 530 nm by using a FL-1H filter of flow cytometer (BD FACS calibur, USA) [17] . Data were analyzed by using Cyflogic software.
Assessment of protein activity involved in anticancer signaling pathway
The assay was done according to the manufacturer's protocol (Santa Cruz Biotechnology Inc, USA) using cell lysate. Drug-treated and control cells were lysed in lysis buffer. The lysed material was centrifuged at 13 000 × g for 15 min at 4 °C and the supernatants were collected. Enzyme-linked immunosorbent assay (ELISA) was carried out with the supernatants to study the expressions of p53, Akt/protein kinase B (PKB), BCL-associated X (Bax), B cell lymphoma 2 (Bcl-2) and caspase 3 quantitatively. The assay was standardized by titration of the different concentrations of antigens and antibodies. Wells were coated with 70 µg of proteins in 100 µL of 0.05 mol/L carbonate buffer (pH 9.6) and kept overnight at 4 °C, in a moist chamber. Flicked the plate to remove the unbound antigen solution and wells were blocked with 1% bovine serum albumin (BSA) in 0.1 mol/L PBS (pH 7.2) for 1 h at 4 °C. Flicked and washed wells thrice with 200 µL of PBS containing 0.05% (volume ratio) Tween-20. Wells were then incubated with primary antibody (1 ∶ 500), diluted in PBS (containing 0.05% Tween-20 and 1% BSA) and kept overnight at 4 °C. Plate was again washed and incubated with specific secondary antibodies (1 ∶ 1 000) for 2 h at 37 °C. Wells were washed further three times as described above. PNPP was used as a colour developer and colour intensity was measured at 405 nm with respect to blank. Glyceraldehyde 3-phosphate dehydrogenase (G3PDH) served as the housekeeping gene.
Analysis of mRNA expressions by semi-quantitative reverse transcriptase-polymerase chain reaction
Total RNA was extracted using TRIzol reagent according to the manufacturer's instructions and the gene expressions were analyzed by semi-quantitative reverse transcriptasepolymerase chain reaction (RT-PCR) [18] to estimate the expression of p53, Akt, Bcl-2, BAX, and caspase 3, at their mRNA level. G3PDH served as the housekeeping gene. Densitometry was performed using Image J software. Primer sequences of RT-PCR were illustrated in Table 1 .
Blinding
The observers were "blinded" during observations as to whether they were observing the "control" or "drug-treated" materials.
Statistical analysis
Statistical analysis was performed by one-way analysis of variance with post-hoc least significant difference tests, using SPSS 14.0 software to identify if the differences were significant among the mean values of different groups. Results were expressed as mean ± standard error of mean. P<0.05 was considered significant.
Results
Effects of PD on the survival of A375 cells
Results of MTT assay revealed that the cell viability gradually decreased from minimal drug concentration to the higher ones in both the cases of 24 and 48 h of incubation after drug treatment. The 50% cell death (LD 50 ) occurred at 348.66 and 203.60 µg/mL of drug employment for the treatment of 24 and 48 h respectively on A375 cells ( Figure 1A ) and the LD 50 values for HeLa and PC3 cells were 704.3 µg/mL (24 h) and 653.78 µg/mL (48 h) ( Figure 1B) , and 595.9 µg/mL (24 h) and 505.44 µg/mL (48 h) ( Figure  1C) , respectively. The cell cytotoxicity on normal PBMCs was also measured in the mentioned dose of PD which showed minimal cytotoxic effects ( Figure 1D ).
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Changes in morphological features
The cellular distortion and the cell blebbing were observed in the drug-treated cells. The cellular distortion was found to be most frequent in cases of higher doses (Figure 2 ).
PD-induced nucleosomal fragmentation
Nucleosomal fragmentation was observed in the drug-treated cells but not in the control ones. The DNA breakage mostly occurred in case of the highest drug dose (D3) applied. See Figure 3 .
Determination of apoptosis and necrosis percentages
After drug treatment the apoptotic percentages increased from 10.11% (control) to 54.93%, 65.20% and 66.73% in cases of D1, D2 and D3 doses, respectively. The necrotic percentages were relatively lower in the drug-treated cells and were 4.76%, 7.08% and 6.80% for D1, D2 and D3, respectively (Figure 4) . 
Detection of accumulation of intracellular ROS by H 2 DCFDA staining
The fluorescence intensity gradually increased in the higher drug doses. D3-treated cells had the most ROS accumulation and had the highest amount of fluorescence ( Figure 5A) . From the FACS analysis with H 2 DCFDA dye, a boost in ROS production was observed ( Figures 5B  and 5C ).
Changes in expression of pro-and anti-apoptotic genes in both mRNA and protein in A375 cells after in vitro treatment with PD
The expression of p53, Bax and caspase 3 was upregulated ( Figure 6A ) and the expression of Akt and Bcl-2 was down-regulated ( Figure 6B ) both at mRNA and protein levels upon drug treatment. G3PDH was used as the housekeeping gene ( Figure 6C ). The changes in the Bcl-2/Bax ratio at both mRNA and protein levels are shown in Table 2 .
Discussion
In the present study, results of cell viability assay with different types of cancer cells, namely, skin melanoma, cervix cancer and prostate cancer for 24 and 48 h, respectively revealed that the treatment with PD reduced the cell viability in vitro for all the cancer types; the effect on A375 cells was more remarkable at 48 h of treatment. Hence, we carried out more in-depth studies on A375 cells. Results on cell viability assay showed that PD reduced the viability of the skin melanoma cells significantly but not the normal cells. Incidentally, a potent anticancer drug should have the potential to eradicate the Journal of Integrative Medicine www.jcimjournal.com/jim cancer cells without being too cytotoxic to normal cells [19] .
Cancer cells are known to have acquired immortality.
A noble anticancer drug should normally be expected to have the property of initiating apoptosis (cell death) to the cancer cells [20] . Consistent with this expectation, PD was found to initiate apoptosis in A375 cells as the main cause of cell death, though it also induced necrosis in a few cells. Results of LDH activity assay supported this contention.
As one major way of combating cancer cells is by killing them, one of the approaches to restrain tumor growth is by activating the apoptotic machinery in the tumor cells [21] . The changes in cellular morphology (e.g., membrane distortion, blebbing), condensation and fragmentation of DNA are two significant characteristic features of apoptosis [22] . Nucleosomal fragmentation was evident through microscopic study of cellular morphology and DAPI staining of the cells.
ROS plays a prodigious role in regulating cell proliferation and removal of unwanted cells through apoptosis [23] . The normal human cells possess certain level of ROS activity, but the cancer cells contain a higher level of ROS activity due to its higher metabolic rates. If the ROS level could be elevated to a further extent to the threshold level, the cells push themselves to apoptosis [24] . This could be a way to control the immortality of cancer cells. In this study, the elevated ROS level was found upon deployment of the drug. The accumulated ROS has the capacity to induce DNA damage [25] . The FACS analysis with H 2 DCFDA fluorescent dye supported the increased cellular ROS generation upon drug treatment.
ROS regulates cell proliferation by down-regulating Akt gene expression [26, 27] which in turn reduces cell proliferation [28] . Expressions of mRNA and protein (by indirect ELISA) showed down-regulation of Akt. This result was in great support of antiproliferative potential of PD. On the other hand, ROS regulates p53 expression. Elevation in ROS level generally up-regulates the "master gene" p53 [29] and this master gene plays a decisive role in whether the damaged DNA will undergo the repair pathway or the fragmentation pathway. When damage is not repairable, generally the cells are led to the apoptotic pathway. Our experimental results, the elevated p53 activity level and DAPI-stained cells, suggest the above event.
Alteration in the levels of Bax and Bcl-2, i.e., the ratio of Bcl-2/Bax, is the decisive factor in determining whether cells will undergo caspase-mediated apoptosis [30, 31] , or be directed towards the survival pathway [32] . In our study, the decrease in Bcl-2 expression and the increase in Bax and Journal of Integrative Medicine www.jcimjournal.com/jim caspase 3 expression both at mRNA and protein levels (by indirect ELISA) were observed. Hence, the altered Bcl-2/ Bax ratio and caspase 3 activation indicate that the cells were directed towards the apoptotic pathway.
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Thus, it can be concluded that PD showed profound anticancer effect on skin melanoma by indulging the cells to apoptosis via elevation of ROS. Our study suggested that the ROS might activate p53 and block Akt and induce apoptosis via caspase 3-mediated pathway. Therefore, the results of the present study would validate the efficacy of PD as an anticancer drug and might encourage the CAM practitioners to use Phytolacca as a supportive medicine as an anti-melanoma drug.
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